Page 45 - Demo

ANALESRANFwww.analesranf.comClinic: Analysis of Infused T Cell Products.Mol Ther 2018; 26: 280-8.https://doi.org/10.1016/j.ymthe.2017.09.008.54. Ausubel LJ, Hall C, Sharma A, et al. Productionof CGMP-Grade Lentiviral Vectors.Bioprocess Int 2012; 10: 32-43. PMCID:PMC3374843.55. Lunghi B, Castoldi E, Mingozzi F, et al. A NovelFactor V Null Mutation Detected in aThrombophilic Patient with PseudoHomozygous APC Resistance and in anAsymptomatic Unrelated Subject. Blood1998; 92: 1463-64. PMID: 9694743.56. Yang TL, Pipe SW, Yang A, et al. Biosyntheticorigin and functional significance of murineplatelet factor V. Blood 2003; 102: 2851-5.https://doi.org/10.1182/blood-2003-04-1224.57. Aden DP, Fogel A, Plotkin S, et al. Controlledsynthesis of HBsAg in a differentiated humanliver carcinoma-derived cell line. Nature1979; 282: 615-6.https://doi.org/10.1038/282615a0.58. Serrano LJ, Garcia-Arranz M, De Pablo-MorenoJA, et al. Development and Characterizationof a Factor V-Deficient CRISPR Cell Model forthe Correction of Mutations. Int J Mol Sci2022; 23: 5802.https://doi.org/10.3390/ijms23105802.59. Liras Mart%u00edn A, Serrano Ramos LJ, Bernal NogueraS, inventores; Universidad Complutense deMadrid y Fundaci%u00f3 Institut de Recerca deL%u2019hospital de La Santa Creu I Sant Pau,assignees. M%u00e9todo in vitro para recuperar laexpresi%u00f3n del gen F5 que codifica el factor Vde la coagulaci%u00f3n. Spanish patentES2785323B2. 2020.60. Liras Mart%u00edn A, De Pablo Moreno JA, RevueltaRueda L, Miguel Batuecas A, Bermejo AlvarezP, Gonz%u00e1lez Brusi L, inventores; UniversidadComplutense de Madrid y Consejo Superiorde Investigaciones Cient%u00edficas, assignees.Mouse model, deficient in factor V. Spanishpatent ES2948817B2. 2024.61. Delev D, Pavlova A, Heinz S, et al. Factor 5mutation profile in German patients withhomozygous and heterozygous factor Vdeficiency. Haemophilia 2009; 15: 1143-53.https://doi.org/10.1111/j.1365-2516.2009.02048.x.42. Xu Y, Li Z. CRISPR-Cas systems: Overview,innovations and applications in human diseaseresearch and gene therapy. Comput StructBiotechnol J 2020; 18: 2401-15.https://doi.org/10.1016/j.csbj.2020.08.031.43. Mojica FJM, Montoliu L. On the Origin of CRISPRCas Technology: From Prokaryotes to Mammals.Trends Microbiol 2016; 24: 811-20.https://doi.org/10.1016/j.tim.2016.06.005.44. Stinson BM, Loparo JJ. Repair of DNA DoubleStrand Breaks by the Nonhomologous EndJoining Pathway. Annu Rev Biochem 2021; 90:137-64. PMID: 33556282.45. Riesenberg S, Kanis P, Macak D, et al. Efficienthigh-precision homology-directed repairdependent genome editing by HDRobust. NatMethods 2023; 20: 1388-99.https://doi.org/10.1038/s41592-023-01949-1.46. Lopes R, Prasad MK. Beyond the promise:evaluating and mitigating off-target effects inCRISPR gene editing for safer therapeutics.Front Bioeng Biotechnol 2024; 11: 1339189.https://doi.org/10.3389/fbioe.2023.1339189.47. Ho D, Quake SR, McCabe ERB, et al. EnablingTechnologies for Personalized and PrecisionMedicine. Trends Biotechnol 2020; 38: 497-518.https://doi.org/10.1016/j.tibtech.2019.12.021.48. Gao K, Kumar P, Cortez-Toledo E, et al. Potentiallong-term treatment of hemophilia A byneonatal co-transplantation of cord bloodderived endothelial colony-forming cells andplacental mesenchymal stromal cells. StemCell Res Ther 2019; 10: 34. PMID: 30670078.49. Olgasi C, Talmon M, Merlin S, et al. PatientSpecific iPSC-Derived Endothelial Cells ProvideLong-Term Phenotypic Correction ofHemophilia A. Stem Cell Reports 2018; 11:1391-406.https://doi.org/10.1016/j.stemcr.2018.10.012.50. High KA, Roncarolo MG. Gene Therapy. N Engl JMed 2019; 381: 455-64.https://doi.org/10.1056/NEJMra1706910.51. Li X, Le Y, Zhang Z, et al. Viral Vector-BasedGene Therapy. Int J Mol Sci 2023; 24: 7736.https://doi.org/10.3390/ijms24097736.52. Naso MF, Tomkowicz B, Perry WL, et al. AdenoAssociated Virus (AAV) as a Vector for GeneTherapy. BioDrugs 2017; 31: 317-34.https://doi.org/10.1007/s40259-017-0234-5.53. Cornetta K, Duffy L, Turtle CJ, et al. Absenceof Replication-Competent Lentivirus in theD%u00e9ficit de factor V y terapias avanzadasAntonio Liras et al. 43 An. R.Acad. Farm.Vol. 91. n%u00ba 1 (2025) %u00b7 pp. 17-44